Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

International Journal of COPD

Volumn 10, Issue , 2015, Pages 439-444

  Nishijima, Yu ^a   Minami, Seigo ^a   Yamamoto, Suguru ^a   Ogata, Yoshitaka ^a   Koba, Taro ^a,b   Futami, Shinji ^a   Komuta, Kiyoshi ^a  

^a OSAKA POLICE HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Chronic obstructive pulmonary disease; Indacaterol; Long acting 2< inf> agonist; Physical activity; Uniaxial accelerometer

Indexed keywords

INDACATEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ACCELEROMETER; AGED; ARTERIAL GAS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; ENERGY EXPENDITURE; EXERCISE INTENSITY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH SURVEY; HUMAN; LUNG FUNCTION TEST; MALE; PATIENT MONITORING; PHYSICAL ACTIVITY; QUALITY OF LIFE; SHORT FORM 36; SMOKING; TREATMENT DURATION; DRUG ADMINISTRATION; DRUG EFFECTS; EXERCISE TOLERANCE; INHALATIONAL DRUG ADMINISTRATION; JAPAN; LUNG; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; JAPAN; LUNG; MALE; MOTOR ACTIVITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLONES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929399593     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S76836     Document Type: Article

References (27)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498–1504.
2. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003;167(4):544–549.
3. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23(1):28–33.
4. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–977.
5. Minakata Y, Sugino A, Kanda M, et al. Reduced level of physical activity in Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2014;52(1):41–48.
6. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331–342.
7. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555.
8. Donohue JF, Fogarty C, Lötvall J, et al; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–162.
9. Kinoshita M, Lee SH, Hang LW, et al; Indacaterol Asian COPD Study Investigators. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology. 2012;17(2):379–389.
10. To Y, Kinoshita M, Lee SH, et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population. Respir Med. 2012;106(12):1715–1721.
11. Kornmann O, Dahl R, Centanni S, et al; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273–279.
12. Buhl R, Dunn LJ, Disdier C, et al; INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797–803.
13. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD. 2011;8(5):340–345.
14. O’Donnell DE, Casaburi R, Vincken W, et al; INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105(7):1030–1036.
15. Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease – a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med. 2014;14(1):158.
16. Hataji O, Naito M, Ito K, Watanabe F, Gabazza EC, Taguchi O. Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:1–5.
17. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from: http://www.goldcopd.org/
18. Kumahara H, Schutz Y, Ayabe M, et al. The use of uniaxial accelerometry for the assessment of physical-activity-related energy expenditure: a validation study against whole-body indirect calorimetry. Br J Nutr. 2004;91:235–243.
19. Sugino A, Minakata Y, Kanda M, et al. Validation of a compact motion sensor for the measurement of physical activity in patients with chronic obstructive pulmonary disease. Respiration. 2012;83(4):300–307.
20. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946.
21. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654.
22. Tsuda T, Suematsu R, Kamohara K, et al. Development of the Japanese version of the COPD Assessment Test. Respir Investig. 2012;50(2):34–39.
23. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51(11):1037–1044
24. Fukuhara S, Ware JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol. 1998;51(11):1045–1053.
25. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Euro Respir J. 2005;26:319–338.
26. Tudor-Locke C, Burkett L, Reis JP, Ainsworth BE, Macera CA, Wilson DK. How many days of pedometer monitoring predict weekly physical activity in adults? Prev Med. 2005;40(3):293–298.
27. Steele BG, Holt L, Belza B, Ferris S, Lakshminaryan S, Buchner DM. Quantitating physical activity in COPD using a triaxial accelerometer. Chest. 2000;117(5):1359–1367.